BACKGROUND A recent increase in Bordetella pertussis without the pertactin protein, an acellular vaccine immunogen, has been reported in the United States. Determining whether pertactin-deficient (PRN(-)) B. pertussis is evading vaccine-induced immunity or altering the severity of illness is needed. METHODS We retrospectively assessed for associations between pertactin production and both cli...

Bordetella pertussis, the causative agent of whooping cough, regulates expression of its virulence factors via a two-component signal transduction system encoded by the bvg regulatory locus. It has been shown by activation kinetics that several of the virulence factors are differentially regulated. fha is transcribed at 10 min following an inducing signal, while ptx is not transcribed until 2 t...

The postemergent herbicide propanil (PRN ; also known as 3,4-dichloropropionanilide) is used on rice and wheat crops and has well-known immunotoxic effects on various compartments of the immune system, including T-helper lymphocytes, B lymphocytes, and macrophages. It is unclear, however, whether PRN also adversely affects cytotoxic T lymphocytes (CTLs) , the primary (1 degrees ) effectors of c...

Four commercially available enzyme immunoassay (EIA) kits were evaluated in comparison with the plaque reduction neutralization (PRN) test for detection of measles virus antibody. The EIA kits, Enzygnost (Behring), Diamedix, Vidas (bioMerieux Vitek), and Measlestat (Biowhittaker), were assessed with two PRN cutoff titers: a PRN titer of 8, the lowest detectable antibody level by the PRN test un...

P.69 pertactin (P.69 Prn), an adhesion molecule from the causative agent of pertussis, Bordetella pertussis, is present in cellular and most acellular vaccines that are currently used worldwide. Although both humoral immunity and cellular immunity directed against P.69 Prn have been implicated in protective immune mechanisms, the identities of CD4(+) T-cell epitopes on the P.69 Prn protein rema...

Pertactin (PRN) is an autotransporter protein produced by all members of the Bordetella bronchiseptica cluster, which includes B. pertussis, B. parapertussis, and B. bronchiseptica. It is a primary component of acellular pertussis vaccines, and anti-PRN antibody titers correlate with protection. In vitro studies have suggested that PRN functions as an adhesin and that an RGD motif located in th...

BACKGROUND PRN prescriptions enablehealthcare staff to respond quickly to the urgent clinical needs of the user without having to contact the responsible clinician (RC). One problem, established amongst most institutions by NICE regarding the use of PRN, is that most of these institutions struggle to keep an updated or full record on the PRN medications. Thus, the aim of this audit was to check...

Acellular vaccines against Bordetella pertussis were introduced in Australia in 1997. By 2000, these vaccines had replaced whole-cell vaccines. During 2008-2012, a large outbreak of pertussis occurred. During this period, 30% (96/320) of B. pertussis isolates did not express the vaccine antigen pertactin (Prn). Multiple mechanisms of Prn inactivation were documented, including IS481 and IS1002 ...

Pro re nata (PRN, as-needed) medication is commonly used in forensic psychiatric inpatient care, but little known about the participation of patients its prescription and administration. This study describes patient PRN treatment care. Data were collected during interviews with 34 inpatients 19 registered nurses a Finnish hospital. The data underwent inductive content analysis. We found that wa...

The present study explores the concept of hybrid pertactin (PRN) molecules for immunizing against Bordetella pertussis. New molecules were designed using an additive/inclusive approach that comprehends the complete sequences/ regions of two different types of pertactin (Prn). PRN molecules bear the two variable R1 regions from Prn1 and Prn2. The genes of Prn1, Prn2 and six variants of PRN were ...